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Abstract
Background: A large proportion of people who inject drugs (PWID) living with hepatitis C virus (HCV) infection
have not been treated. It is unknown whether inclusion of HCV diagnostics and treatment into integrated substance
use disorder treatment and care clinics will improve uptake and outcome of HCV treatment in PWID. The aim is to
assess the efficacy of integrating HCV treatment to PWID and this paper will present the protocol for an ongoing trial.
Methods: INTRO-HCV is a multicentre, randomised controlled clinical trial that will compare the efficacy of integrated
treatment of HCV in PWID with the current standard treatment. Integrated treatment includes testing for HCV,
assessing liver fibrosis with transient elastography, counselling, treatment delivery, follow-up and evaluation provided
by integrated substance use disorder treatment and care clinics. Most of these clinics for PWID provide opioid agonist
therapy while some clinics provide low-threshold care without opioid agonist therapy. Standard care involves referral
to further diagnostics, treatment and treatment follow-up given in a hospital outpatient clinic with equivalent
medications. The differences between the delivery platforms in the two trial arms involve use of a drop-in
approach rather than specific appointment times, no need for additional travelling, less blood samples taken
during treatment, and treatment given from already known clinicians. The trial will recruit approximately 200 HCV
infected individuals in Bergen and Stavanger, Norway. The primary outcomes are time to treatment initiation and
sustained virologic response, defined as undetectable HCV RNA 12 weeks after end of treatment. Secondary
outcomes are cost-effectiveness, treatment adherence, changes in quality of life, fatigue and psychological well-
being, changes in drug use, infection related risk behaviour, and risk of reinfection. The target group is PWID with
HCV diagnosed receiving treatment and care within clinics for PWID.
Discussion: This study will inform on the effects of an integrated treatment program for HCV in clinics for PWID
compared to standard care aiming to increase access to treatment and improving treatment adherence. If the
integrated treatment model is found to be safe and efficacious, it can be considered for further scale-up.
Trial registration: ClinicalTrials.gov.no. NCT03155906.
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Background
Hepatitis C virus (HCV) is endemic among people who
inject drugs (PWID) [1]. Globally 40% of the HCV dis-
ease burden is attributable to injecting drug use and in
Western Europe this fraction is 64%. Recently, highly ef-
fective direct-acting antiviral (DAA) treatment of HCV
infection became available, prompting the World Health
Organisation (WHO) to develop a global strategy to
eliminate HCV by 2030. However, as PWID represent
the majority of HCV patients in high income countries
there are challenges particular to this group that must
be addressed if elimination is to be achieved [2].
Chronic HCV infection is a slowly progressive disease
that may lead to liver cirrhosis and subsequent complica-
tions, including hepatocellular carcinoma (HCC), liver fail-
ure and early deaths [3, 4]. Among HCV-infected people
with opioid dependence, one-third develops advanced
liver disease within three decades [5] and within this
group, liver disease and drug overdose becomes equally
common causes of death among individuals over the age
of 50 years [6]. Reports from opioid agonist therapy
(OAT) clinics in Norway indicate that more than half of
patients receiving OAT have chronic HCV infection [7].
This represents an ageing cohort often at high risk of de-
veloping advanced liver disease [8]. Ongoing injecting risk
behaviour with risk of onwards HCV transmission is also
prevalent in this population [9]. Thus, reaching these indi-
viduals with HCV treatment is of critical importance both
to reduce HCV disease burden and HCV transmission.
Until 2014, HCV treatment was interferon-based with
low efficacy, considerable adverse effects and accordingly
low treatment uptake particularly among PWID [10]. The
perceived high risk of reinfection following successful
treatment may also have represented a barrier to HCV
treatment in this population [9]. The current availability
of tolerable and highly efficient all-oral DAA treatment
has changed the HCV care paradigm and led to significant
therapeutic optimism. However, The World Hepatitis
Summit in 2017 expressed concern for the lack of inte-
grated approaches, acknowledging the need for new
models of patient-centred service delivery and recognised
the need for integrated collaborative approaches [11]. To
achieve this, new models of care must be developed.
Models focusing on interdisciplinarity, availability and ac-
cessibility, with decentralised clinics and frequent follow-
ups have been suggested to be effective [12–14]. However,
reviews have called for further evidence on the effect of in-
tegrated treatment for people with substance use disorders
[15, 16].
In Western Norway, more specifically in the cities of
Stavanger and Bergen, OAT treatment is administered
in an integrated treatment and care model with follow-
up by physicians, nurses, social workers and psycholo-
gists on nearly a daily basis with observed intake of
OAT medications [17]. PWID not receiving OAT are of-
fered care at municipal low-threshold health and care
clinics. Thus, the models already in place could be a
well-suited platform to evaluate the effect of integrated
HCV care to PWID.
Objectives
This paper presents the protocol of the INTRO-HCV
study. The primary objective of the INTRO-HCV study is
to compare the efficacy of integrated treatment of HCV in
PWID with the current standard treatment. Integrated
treatment includes testing for HCV, assessing liver fibrosis
with transient elastography, counselling, treatment deliv-
ery, follow-up and evaluation provided by integrated sub-
stance use disorder treatment and care clinics. Most of
these clinics for PWID provide OAT while some clinics
provide low-threshold care without OAT. Standard care
involves referral to further diagnostics, treatment and
treatment follow-up given in a hospital outpatient clinic
with equivalent medications.
Secondary objectives are comparison of treatment
adherence between the integrated and standard arms, as-
sessment of changes in quality of life, fatigue and psy-
chological well-being before and after HCV treatment,
as well as changes in drug use, infection related risk be-
haviour, and risk of reinfection among those with
sustained virologic response (SVR). Further, we will esti-
mate cost-effectiveness of integrated HCV care and inci-
dence and prevalence of HCV infection among PWID in




This is a multicentre, randomised controlled clinical
trial.
Study settings and participants
The target group will be PWID receiving integrated sub-
stance use disorder treatment and care from involved
clinics in Bergen and Stavanger who are chronically in-
fected with HCV and eligible for treatment according to
national guidelines.
Department of Addiction Medicine at Haukeland Uni-
versity Hospital in Bergen have adopted an integrated
treatment and care model for PWID receiving OAT. In
Bergen, OAT outpatient clinics have been established in
each district where the patients are followed up by
health and social workers on a nearly daily basis with
observed intake of the OAT medications such as bupre-
norphine or methadone [17]. Every month, the OAT
clinics have a total of 6000 visits among the approxi-
mately 500 patients. This group of patients have a large
morbidity burden and have to a limited extent been able
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to get access to other standard health care. Each of the
OAT outpatient clinics is staffed by a consultant and a
physician/ specialist registrar in addiction medicine in
addition to nurses, social workers, and psychologists. A
close collaboration has been established between the De-
partment of Addiction Medicine and the Agency for ad-
diction and mental health in Bergen municipality, who is
responsible for the care in several of the primary health
clinics for PWID in Bergen. Clinics for PWID in the
Stavanger area have a relatively similar structure and are
responsible for the OAT treatment of approximately 460
patients within their area. People receiving OAT in
Norway are generally prescribed buprenorphine or
methadone, to some degree additional benzodiazepines
but rarely other opioids. The treatment model in Bergen
and Stavanger is a well-suited platform to test integra-
tion of HCV treatment aiming to improve the health
and life span of a vulnerable group, and at the same time
gathering knowledge which traditionally have been diffi-
cult to obtain.
Eligibility criteria
For the randomised trial, inclusion will be based on the
following criteria
 PWID receiving OAT or low-threshold care from an
included clinic with follow-up on weekly basis
 Chronically infected with HCV (HCV RNA positive
measured at least twice over 6 months)
 Eligible for treatment according to national
guidelines (criteria specified below)
 Giving informed consent
Enrolment started May 2017. At that time, eligibility
for treatment according to Norwegian guidelines was de-
fined as follows:
– Genotype 1 and 4 infection independent of stage of
liver fibrosis.
– Genotype 2 and 3 infection with significant liver
fibrosis.
Transient elastography (FibroScan) will be used in the
screening of significant fibrosis defined as measurements
above 7.0 kPa [18, 19].
Thus, some patients needed to wait some months after
HCV diagnosis before initiating treatment. From 1st of
February 2018, all patients with chronic HCV were eli-
gible for treatment according to the updated national
(independent of stage of liver fibrosis).
The following exclusion criteria will be used:
 HIV co-infection
 Severe extrahepatic HCV manifestations (e.g.
cryoglobulinemia)
 Membranoprolifereative glomerulonephritis
(MPGN) or renal failure (estimated glomerular
filtration rate < 30 ml/min/1.73 m2)
 Decompensated liver disease (Child-Pugh score > 6
points, class B and C)
Encephalopathy in Child-Pugh will be assessed accord-
ing to the West Haven criteria [20].
 Currently receiving treatment for HCV
Interventions
Participants randomised to standard care are first assessed
and diagnosed at the integrated care clinics for PWID by
nurse and physician and when found in need of treatment,
are referred to a hospital clinic for further assessment and
treatment. The standard care generally involves being re-
ferred to the medical outpatient clinic. The clinic will send
a letter informing on time of appointment usually some
weeks later and could involve some additional blood
samples and imaging before initiating DAA treatment.
Subsequently, an electronic prescription is given in a con-
sultation where treatment is initiated. The medications
given are in principle equivalent in the two trial arms.
Most will receive medication combinations of either elbas-
vir/grazoprevir 50/100mg or sofosbuvir/ledipasvir 400/90
mg (for genotype 1 and 4) or sofosbuvir/velpatasvir 400/
100mg (for genotype 2 and 3) – sometimes also in com-
bination with voxilaprevir 100mg or ribavirin 200mg due
to specific clinical indications. Glecaprevir/pibrentasvir
100/40mg may also be used in special cases. Patients are
generally given follow-up consultations every 4 weeks dur-
ing treatment and a post-treatment assessment 12 weeks
after completed treatment. Typically, this involves a total
of 4–5 consultation visits at the hospital.
Participants randomised to integrated treatment are
given integrated assessment and treatment at the clinics
for PWID (by nurse and physician). For those found to
be in need of treatment, medications are made available
by a nurse that gives follow-up for OAT or low-
threshold care for PWID. Follow-up during treatment is
given in parallel with delivery of OAT treatment and
other care. At 12 weeks post treatment, a research nurse
takes blood samples to assess the treatment effect.
The differences between the delivery platforms in the
two trial arms involve the following main aspects:
– Need of travel: Standard care involves transportation
to a hospital clinic – a distance that ranges from 1
to about 25 km in distance (with potential travel
costs) while integrated treatment does generally not
require need for additional travel
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– Need to come to specific appointment times:
Standard treatment is generally given based on
appointments while integrated treatment is generally
given in a drop-in approach
– Frequency of blood samples during treatment is mainly
depending on clinical indication (e.g. suspected adverse
effects or complications). Less blood sampling may
reduce discomfort
– Time used and potential for overlapping
appointments: For standard treatment there is a
higher risk that the appointment time overlap with
other important activity including other health care,
while for integrated treatment appointment time is
generally planned together with patient
– Need to meet new clinicians for health care: In
integrated care clinics, follow-up is generally done
by already familiar contact nurse and physician pro-
viding regular follow-up. Standard treatment is given
in hospital clinic by clinicians often unfamiliar to the
patients
Outcomes
Primary outcome measures are
 Sustained virologic response will be assessed by
undetectable HCV RNA at 12 (range 10–14) weeks
after completed treatment. The virologic blood
samples in Bergen will be analysed at Department
for microbiology (accredited by ISO-standard
15,189) after being centrifuged at each study clinic
before transfer
 Time to treatment initiation after diagnosing HCV
in need of treatment (in line with national
guidelines). This will be assessed with time-to-event
analyses. We also plan to present stratified analyses
on patient-related delay and system-related delay
Secondary outcome measures are
 Treatment adherence assessed by proportion of
doses observed being taken in intervention group
and reported obtainment from pharmacies of the
prescribed drugs combined with self-reported ques-
tions on adherence collected at 4, 8 (and 12 for
treatment recommended beyond 8 weeks) weeks
after treatment initiation. The self-reported ques-
tions categorise adherence during last four weeks
into rarely, sometimes but less than half of the
doses, between 50 and 80% of the doses, more than
80% of the doses, and always (95% of doses or
more). These outcome measures will be collected at
the OAT/PWID clinics
 Reinfection will be defined as HCV RNA recurrence
following SVR. Incidence rates will be calculated
using person-time techniques assuming a Poisson
distribution. All patients achieving SVR will be
assessed for reinfection 3 months after treatment
and then annually. HCV RNA positive samples will
be further analysed with a quantitative HCV RNA
count, HCV genotyping. Relapse is defined as pres-
ence of the same virus strain at the time of diagnosis
and at the end of treatment. Anti-HIV and use of
other drugs will also be assessed
 Changes in quality of life will be assessed with the
questionnaire EQ-5D-5 L (https://euroqol.org/eq-5d-
instruments/) in addition to a self-reported question
on happiness on a 0 to 10 scale at 12 weeks after
treatment compared to before treatment
 Changes in fatigue will be assessed with the Fatigue
Symptom Scale at 12 weeks after treatment
compared to before treatment
 Changes in psychological well-being will be assessed
with the Norwegian validated translation version of
Hopkins Symptom Checklist (SCL-10) at 12 weeks
after treatment compared to before treatment
 Assessment of changes in substance use will be
assessed with self-reported use of the following drug
categories the last 30 days, the last 12 months and
ever: Alcohol, tobacco, cannabis, amphetamines, co-
caine, heroin, other opioids not prescribed by phys-
ician, benzodiazepines or z-hypnotics, hallucinogens,
solvents and gamma hydroxybutyrate (GHB), ana-
bolic steroids and other drugs at 12 weeks after
treatment compared to before treatment
 Assessment of changes in injecting risk behaviour
will be performed with questions assessing sharing
of needles and other user equipment before and
after HCV treatment at 12 weeks after treatment
compared to before treatment
 Health provider costs by using an ingredients
approach, where quantities used and the value (or
price) of each unit is estimated in the both trial
arms. Health care costs will be used in a health
economic evaluation, where both costs per cured
patient and per Quality Adjusted Life Year (QALY)
gained will be estimated.
Sample size
We expect higher rates of treatment success in the inter-
vention arm receiving integrated treatment compared to
the standard arm. The power calculation is based on the
following assumptions:
– The power is set at 90% with a two-sided alpha (α)
error of 5%.
– Comparison of SVR at 12 weeks.
– Up to 33% lost to follow-up at 12 weeks after
treatment.
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– Equal proportions between the groups, 30% higher
rates of successfully cured in integrated compared to
standard treatment (e.g. 50% in the standard arm
and 80% in the intervention arm).
– Statistical power calculations in Stata.
Based on these assumptions, 87 persons are required
in intervention arm and 87 persons in the control arm.
Reducing the differences in rates of successfully cured to
25% while reducing power to 80%, 99 persons in each
arm would be required (or 66 persons if assuming no
lost-to-follow-up).
Recruitment
All PWID receiving OAT treatment or low-threshold
care from included clinics will be considered the refer-
ence target population. As part of an annual clinical as-
sessment, patients will be informed about the study and
asked for consent to participation. All patients in target
population will be offered annual clinical assessment and
study participation. For those giving informed consent,
an extended clinical assessment will be offered and those
diagnosed with chronic HCV will be randomised for the
intervention.
Allocation and blinding
We will use block randomisation with a 1:1 ratio using
blocks of 10 to ensure relatively similar distribution be-
tween both arms throughout different time periods of the
trial. Randomisation will be electronically registered. The
randomisation will be stratified by site/county (site 1: Ber-
gen/Hordaland and site 2: Stavanger/ Rogaland).
Even though complete blinding is regarded as difficult
and would probably come at a cost of reduction in exter-
nal validity [21], there will be some degree of blinding/
masking. Randomisation will be disclosed to physician
and other health care staff providing treatment and
follow-up for PWID, but not to research nurses conduct-
ing data collection for outcomes. Patients will be informed
of which intervention arm they are randomised to and the
form of follow-up they will receive, but not on other
follow-up alternatives they do not receive and what the
hypotheses for the study are.
Data collection and management
Data collection and follow-up will be given in line with
Table 1 and Fig. 1.
The blood samples for the primary outcome measures
will be collected at the OAT/PWID clinics for partici-
pants randomised to integrated care and at the hospital
outpatient clinic for the participants randomised to
standard care. However, for patients who do not come
for assessment at the hospital clinic 12 weeks after treat-
ment, efforts will be made to collect these blood samples
at the OAT/PWID clinic. For the remaining outcome
measures, these will be measured at the OAT/PWID
clinics by research nurses through a structured interview
for both participants randomised to standard and inte-
grated treatment.
Analyses and statistical methods
A detailed plan for analysis will be developed before data
export and analysis. We will in this section outline some
of the principles which will be used to guide decisions
during data analysis. Analysis methods will follow the
CONSORT and SPIRIT guidelines as far as possible [22–
24]. All tests will be two-sided. Descriptive results and effi-
cacy estimates will be presented with 95% confidence in-
tervals. The statistical significance is set at p < 0.05.
Potential confounders may be considered for adjustment
if they are imbalanced at baseline (with assumed meaning-
ful differences). Missing data will be considered, and ap-
propriate imputations based on pre-defined assumptions
will be done when necessary (as described in detailed plan
of analysis). Categorical variables will be summarized as
percentages and continuous variables as medians with
interquartile ranges or means with standard deviation for
variables with a Gaussian distribution. The main out-
comes will be analysed with time-to-event analysis (Cox
regression and Kaplan-Meier plots) and generalised linear
models/logistic regression. A separate health economic
evaluation will assess the incremental cost-effectiveness
ratio of the intervention arm compared to the control
arm. A Markov model will be used, and the analysis will
be exhibited in TreeAge. Results will be presented as cost
per QALYs of integrated versus standard HCV care.
Potential harms and data monitoring
Those who participate in the study will be randomised to
one of two different follow-up programs. It is possible that
the treatment follow-up in the integrated treatment is in-
ferior in quality to the standard treatment. Several mea-
sures have been taken to ensure sufficient quality of the
treatment follow-up and to safeguard through detection of
potential severe adverse effects (SAEs). It is also possible
that the integrated treatment will lead to better treatment
adherence and response and thus less morbidity.
There is a risk of hepatic decompensation during treat-
ment of patients with cirrhosis and portal hypertension
[25]. To reduce this risk, patients with decompensated cir-
rhosis (Child Pugh class C or D) will be excluded. Further,
there is a small risk of reactivation of hepatitis B virus
among patients with occult infection after treatment for
HCV and potentially liver failure unless properly assessed
[26]. However, patients with a possible occult hepatitis B
infection (anti-HBc positive, anti-HBs negative and HBsAg
negative) will be closely followed up by weekly blood sam-
pling during the first 4 weeks of treatment including liver
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enzyme assessments and HBV DNA (PCR) in order to be-
ing able to identifying reactivation in early stages.
All grade 3 and 4 adverse effects are considered as SAE
and will be reported as such. For the evaluation of safety,
all SAEs occurring during the trial follow-up period will
be reported on the Clinical Report Form using a national
registration form for medication related side effects. A
copy of the form will be sent to RELIS Vest in addition to
a copy sent to the clinical coordinators and steering com-
mittee reviewing all cases. Adverse effects grade 1 or 2 will
be assessed through a questionnaire.
All SAEs will be followed until resolution or until a
stable clinical end-point is reached. All measures re-
quired for SAE management and the ultimate outcome
of the SAE will be recorded.
Similarly, there is potentially a risk for development of
HCV resistant to direct acting antiviral medications, par-
ticularly among patients not completing treatment. Ef-
forts will be made to avoid treatment failure and aiming
for a secondary curative treatment among those failing
first treatment. There will not be an independent data
monitoring committee. The study coordination unit will
be responsible to ensure adherence to the protocol,
quality of the study and ethical conduct.
Discussion
The research project will improve knowledge on the im-
pact on health care organisation and structure on patient
outcomes. We will assess a platform aiming for easier
access to treatment of HCV among PWID who have
been difficult to reach with ordinary health services. In-
tegrated treatment models may be an opportunity to in-
crease adherence to HCV treatment and evaluate
collaborative care in light of access to direct acting anti-
viral medications. The treatment platform could reduce
the burden of HCV among this patient population and
could contribute to HCV elimination. We will test this
with a randomised controlled trial done in parallel with






























± 7 ± 7 ± 7 ± 14 ± 60
Physician assessment X X X
Research nurse
assessment
X X X X
- Informed consent X
- Eligibility assessment X X X
- Follow-up by staff deliv-
ering treatment and pro-
viding information
(several times weekly)
X X X X
- Clinical assessment X X b b b b X
- Counselling on
prevention
X X X X X X
Elastographya X (X) X
Lab tests
- Viral testing X X X
Full blood count and
transaminases
X b b b X X
HSCL-10 (mental health) X X X
FAS (fatigue symptoms) X X X
EQ-5D-5 L (quality of life) X X X
Infection risk behaviour X X X
Substance use patterns X X X
HCV genotyping and viral
load
X X X
aElastography after treatment will be assessed in Bergen and not in Stavanger due to elastography availability only in hospital clinic and not outpatient clinic
bAdditional tests will be taken on clinical indication
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an observational study assessing HCV reinfections, other
infections including HIV, and liver disease severity.
Our trial involves some limitations and several
strengths. For the trial it is difficult to ensure
complete blinding, however, we will aim for blinding
of data collectors and some degree of blinding for
participants. The study is also funded from public
sources ensuring independency. We also have a bio-
logical primary outcome. Thus, substantial informa-
tion biases are considered unlikely. The study is
individually randomised minimizing potential con-
founding. The study population of PWID will include
a large proportion struggling to obtain standard care.
This will not be applicable to all groups of people
with substance use disorders. For people with sub-
stance use disorders with higher levels of functioning
and less need for regular treatment follow-up, the
need for treatment integration might not be as rele-
vant. The study setting is also very suitable to test
out treatment integration. The time prior to change
in the national guidelines for treatment of HCV made
it necessary for some people to delay HCV treatment
initiation. This might impact negatively on the treat-
ment outcomes, but probably is balanced between the
arms. Further, most of the participants will be treated
after the guideline changes where treatment is now
available independent of stage of liver fibrosis. Subse-
quently, we assume that this effect will not be sub-
stantial. The study might be well suited to assess
some biological effects of HCV infection such as to
which extent HCV contributes to fatigue, reduced
quality of life, occurrence of mental disorders and
continued drug use. The study size should be suffi-
cient to answer the primary objectives with high pre-
cision and is assumed to have adequate precision also
for secondary objectives. In terms of safety, the fre-
quent follow-up of PWID could improve detection of
potential adverse effects of the applied medications.
One can see trials on a continuity from efficacy trials
optimising internal validity through homogeneous
population to effectiveness trials optimising external
validity with a more heterogeneous population. This
trial is tending towards the effectiveness side of the
spectrum. An alternative design could have been a
stepped-wedge trial which could have required slightly
smaller sample sizes and would also be well opted to
measure effectiveness of integrated treatment. How-
ever, we expect to have enough participants to meet
the sample size requirements. On the other side,
stepped-wedged trials generally take longer time to
conduct due to the time delay. In addition, our more
conventional trial design is less vulnerable to con-
founding from time trends.
Our assessment will also inform future health policy
on efficiency by using standard methods of cost-
effectiveness analysis taking both the expected effective-
ness and provider costs of the intervention into consid-
eration. Even though there is evidence on the cost-
effectiveness of standard DAA in HCV treatment regi-
mens; there is limited evidence for the cost-effectiveness
Fig. 1 Overview of follow-up for the study * The arrows are indications of when the various measured are timed
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of alternative scale-up scenarios taking the complex be-
havior of PWID into account [27].
If the integrated treatment model for HCV in clinics
for PWID compared to standard care is found to be safe
and efficacious in terms of increasing access and im-
proving treatment outcomes, this model could be con-
sidered for further scale-up.
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